Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32

BACKGROUND: BM32 is a grass pollen allergy vaccine based on recombinant fusion proteins consisting of nonallergenic peptides from the IgE-binding sites of the 4 major grass pollen allergens and the hepatitis B preS protein. OBJECTIVE: We sought to study the safety and clinical efficacy of immunother...

Descripción completa

Detalles Bibliográficos
Autores principales: Niederberger, Verena, Neubauer, Angela, Gevaert, Philippe, Zidarn, Mihaela, Worm, Margitta, Aberer, Werner, Malling, Hans Jørgen, Pfaar, Oliver, Klimek, Ludger, Pfützner, Wolfgang, Ring, Johannes, Darsow, Ulf, Novak, Natalija, van Wijk, Roy Gerth, Eckl-Dorna, Julia, Focke-Tejkl, Margarete, Weber, Milena, Müller, Hans-Helge, Klinger, Joachim, Stolz, Frank, Breit, Nora, Henning, Rainer, Valenta, Rudolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392176/
https://www.ncbi.nlm.nih.gov/pubmed/29361332
http://dx.doi.org/10.1016/j.jaci.2017.09.052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392176/
https://www.ncbi.nlm.nih.gov/pubmed/29361332
http://dx.doi.org/10.1016/j.jaci.2017.09.052

Ejemplares similares